Automated Animal High Throughput Screening Model for Anti Epilepsy Drugs

This work is a business plan to evaluate an anti-epilepsy drug development technology that has commercial potential to be used as a high throughput screening method. Epilepsy is such a prevalent neurological disorder that it affects over 1% of the general population worldwide. The anti-epilepsy drug (AED) market is in its steady growth along with the high throughput screening (HTS) market, as many biotech and pharmaceutical companies take a disintegrated value chain approach in order to capture more value during the drug development process, which could take over 10 years and cost up to $1 billion. After extensive market research and financial analyses, it is found that the technology could spawn a business that could generate $15 million per year with an outstanding IRR of 72% for the first wave of investors.